Yazar "Horakova, D." için listeleme
-
Aggressive form of multiple sclerosis can be predicted early after disease onset
Malpas, C. B.; Manouchehrinia, A.; Sharmin, S.; Roos, I.; Horakova, D.; Havrdova, E. K.; Iuliano, G. (Sage Publications Ltd, 2019)… -
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis
Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Barnett, M. (Sage Publications Ltd, 2017)… -
Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.
Spelman, T.; Harvrdova, E. K.; Horakova, D.; Izquierdo, G.; Kalincik, T.; Lugaresi, A.; McCombe, P. (Sage Publications Ltd, 2018)… -
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS
Spelman, T.; Havrdova, E.; Horakova, D.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)… -
Defining secondary progressive multiple sclerosis
Lorscheider, J.; Buzzard, K.; Jokubaitis, V.; Spelman, T.; Havrdova, E.; Horakova, D.; Van Pesch, V. (Sage Publications Ltd, 2015)… -
Determinants of disability accumulation in secondary-progressive multiple sclerosis.
Lizak, N.; Malpas, C.; Sharmin, S.; Havrdova, E.; Horakova, D.; Izquierdo, G.; Kalincik, T. (Sage Publications Ltd, 2018)… -
Determinants of MS re-activation after discontinuing therapies
Husin, H.; Wallace, J.; Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. Kubala; Hupperts, R. (Sage Publications Ltd, 2018)… -
Determinants of therapeutic lag in relapsing multiple sclerosis
Roos, I.; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2019)… -
Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis
Le, M. V. H.; Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Granella, F. (Sage Publications Ltd, 2018)… -
Early clinical predictors of severe MS
Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Spitaleri, D. (Sage Publications Ltd, 2018)… -
The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis
Brown, J. W. L.; Coles, A.; Horakova, D.; Havrdova, E.; Trojano, M.; Izquierdo, G.; McCombe, P. (Sage Publications Ltd, 2017)… -
Evaluation of common criteria of progression of disability in a large observational cohort
Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Terzi, M. (Sage Publications Ltd, 2014)… -
Individual response to disease modifying therapies: a global observational cohort study
Kalincik, T.; Sobisek, L.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Granella, F. (Sage Publications Ltd, 2016)… -
Modifiers of the effectiveness of MS immunotherapies
Kalincik, T.; Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Van Pesch, V. (Sage Publications Ltd, 2019)…